The product uses a technology similar to that of classic flu vaccines.
The manufacturer even speaks of an "alternative vaccine solution" against Corona.
Berlin - The corona vaccination numbers in Germany have recently increased only slowly, among other things because some people are hesitant about the new vaccines. One of them is apparently the German national player Joshua Kimmich from FC Bayern Munich. He said he had "a few personal concerns, especially when it comes to the lack of long-term studies." This "should be respected, especially as long as you stick to the measures," said the 26-year-old.
As the
picture claims to have found out
in its “Insider” format, Kimmich is probably hoping for a “dead vaccine” (
tz.de *
reported).
In contrast to the well-known mRNA vaccines such as Moderna and Biontech or vector vaccines such as Johnson & Johnson and Astrazeneca, the pathogens contained in dead vaccines are already killed.
However, none of these vaccines against corona have yet been approved.
Corona: Valneva wants to offer "alternative solution" with dead vaccine
But a few days ago the Franco-Austrian company Valneva announced “positive first” results from the clinical phase 3 study for its vaccine candidate.
Compared to Astrazeneca, the test subjects had a higher mean value of neutralizing antibodies, the company said.
The agent is also "generally well tolerated".
According to the information, 4012 people aged 18 and over in the UK had participated in the study.
"These results suggest that this vaccine candidate is well on its way to playing an important role in the fight against the pandemic," said Bristol University study director and professor of pediatrics, Adam Finn.
Valneva Managing Director Thomas Lingelbach announced that the company wanted to get its vaccine candidate approved "as soon as possible" in order to "offer people who have not yet been vaccinated an alternative vaccine solution".
The first steps towards an application for approval with the British health authority MHRA have already been taken.
Great Britain cancels Valneva's order for 100 million Covid Impdoses
Around a month ago, according to the Franco-Austrian company, Great Britain canceled its order for 100 million vaccine doses.
This was possible due to a contractual clause.
The UK government alleged that Valneva had failed to meet its obligations.
Valneva denied the allegation without further explanation.
This was a hard blow for the group as the UK has been its only customer for the Covid vaccine so far.
The share price plummeted 40 percent after the announcement.
The French government then assured that the EU would continue to be interested in the vaccine.
After the study results were announced on Monday, Valneva shares rose by more than 30 percent at the start of trading on the Paris Stock Exchange.
The Valneva vaccine has a similar structure to classic flu vaccines and should be able to be stored in normal refrigerators.
So far, no vaccine with this mode of action has been approved in the EU.
(dpa / frs)